A new treatment for IgA nephropathy, a chronic kidney disease, is showing promising long-term results. Final data from a Phase 3 clinical trial demonstrate that iptacopan significantly reduces proteinuria – a key marker of kidney damage – and slows disease progression over 24 months. This offers a potential new hope for the tens of thousands of people living with this often-debilitating condition. IgA nephropathy, also known as Berger’s disease, occurs when antibodies build up in the kidneys, leading to inflammation and, eventually, kidney failure.
The trial, involving 232 participants, revealed that iptacopan, developed by BridgeBio Pharma, achieved a statistically significant and clinically meaningful reduction in proteinuria compared to placebo. The findings, recently published, build upon earlier positive results from the trial and provide further evidence of the drug’s efficacy. Researchers followed patients for two years, assessing changes in kidney function and levels of protein in the urine. The data suggest iptacopan could potentially delay or even prevent the need for dialysis or kidney transplantation for some patients.
Iptacopan works differently than current standard treatments. It’s a first-in-class oral selective factor B inhibitor, meaning it targets a specific part of the complement system – a part of the immune system that plays a role in inflammation. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) explains that in IgA nephropathy, the complement system becomes overactive, contributing to kidney damage. By selectively inhibiting factor B, iptacopan aims to reduce this overactivity without completely suppressing the immune system, potentially minimizing side effects.
Significant Reduction in Proteinuria Observed
The primary endpoint of the trial was the change in urine protein-to-creatinine ratio (UPCR) from baseline to month 12. The final 24-month data confirmed the initial findings: patients treated with iptacopan experienced a significantly greater reduction in UPCR compared to those receiving a placebo. Specifically, the least squares signify difference in UPCR change from baseline to month 24 was -0.76 g/g (95% confidence interval, -1.05 to -0.47; P < 0.001). This indicates a substantial decrease in protein leakage into the urine, a hallmark of kidney damage.
Beyond proteinuria, the trial also assessed the impact of iptacopan on estimated glomerular filtration rate (eGFR), a measure of kidney function. While the difference between the iptacopan and placebo groups in eGFR change was not statistically significant at 24 months, the data suggest a trend towards slower kidney function decline in the iptacopan group. Researchers are continuing to analyze these data to better understand the long-term effects on kidney function. Mayo Clinic details the importance of monitoring eGFR in managing kidney disease.
Safety and Tolerability Profile
Iptacopan demonstrated a generally favorable safety profile in the trial. The most common adverse events were upper respiratory tract infections, headache and diarrhea, which were generally mild to moderate in severity. Serious adverse events were infrequent and occurred at similar rates in both the iptacopan and placebo groups. Notably, there were no reports of increased susceptibility to infections, a concern with some other immunosuppressive therapies used to treat kidney diseases.
However, it’s key to note that iptacopan carries a boxed warning regarding increased risk of meningococcal infections. Patients receiving iptacopan are required to be vaccinated against meningococcal disease before starting treatment and monitored for signs and symptoms of infection. This precaution is due to the drug’s impact on the complement system, which plays a role in fighting off certain bacterial infections.
Who is Affected by IgA Nephropathy?
IgA nephropathy affects an estimated 100,000 to 150,000 people in the United States, though many remain undiagnosed. The disease is more common in certain populations, including people of Asian and Caucasian descent. Symptoms can vary widely, ranging from microscopic blood in the urine to visible blood, protein in the urine, high blood pressure, and swelling in the hands and feet. In some cases, the disease progresses slowly over many years, while in others, it can lead to kidney failure within a few years.
Current treatments for IgA nephropathy primarily focus on managing symptoms and slowing disease progression. These include blood pressure control, ACE inhibitors or ARBs (medications that protect the kidneys), and, in some cases, corticosteroids or other immunosuppressants. However, these treatments are not always effective, and many patients continue to experience disease progression despite treatment.
Next Steps and Regulatory Review
BridgeBio Pharma has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for iptacopan as a treatment for IgA nephropathy. The FDA is currently reviewing the application, and a decision is expected in the coming months. If approved, iptacopan would represent a significant advance in the treatment of this challenging disease. The company is also exploring the potential of iptacopan in other complement-mediated diseases.
The availability of iptacopan could significantly improve the quality of life for individuals with IgA nephropathy and potentially reduce the burden on the healthcare system. Ongoing research will continue to refine our understanding of the disease and identify new therapeutic targets. For the latest updates on iptacopan and IgA nephropathy, patients and healthcare professionals can visit the BridgeBio Pharma website and the National Kidney Foundation website.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Have you or a loved one been affected by IgA nephropathy? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might find it helpful.
